Moreover, the 36-month beta value for ALZN is -0.16. Analysts have varying opinions on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for ALZN is 6.32M and currently, short sellers hold a 3.54% of that float. On May 09, 2025, ALZN’s average trading volume was 406.97K shares.
ALZN) stock’s latest price update
The stock price of Alzamend Neuro Inc (NASDAQ: ALZN) has dropped by -9.40 compared to previous close of 0.60. Despite this, the company has seen a fall of -18.81% in its stock price over the last five trading days. globenewswire.com reported 2025-05-07 that Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in healthy subjects ATLANTA, May 07, 2025 (GLOBE NEWSWIRE) — Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar disorder (“BD”), major depressive disorder (“MDD”) and post-traumatic stress disorder (“PTSD”), today announced its partnership with Mint Labs Inc. d/b/a QMENTA (“QMENTA”), a leading medical imaging artificial intelligence (“AI”) company, to support its five upcoming Phase II clinical trials of AL001 at Massachusetts General Hospital. QMENTA’s cloud-based platform will manage and analyze medical imaging data throughout the trials, ensuring regulatory compliance, enhancing operational efficiency and supporting data management.
ALZN’s Market Performance
Alzamend Neuro Inc (ALZN) has experienced a -18.81% fall in stock performance for the past week, with a -38.65% drop in the past month, and a -54.62% drop in the past quarter. The volatility ratio for the week is 13.15%, and the volatility levels for the past 30 days are at 9.03% for ALZN. The simple moving average for the past 20 days is -21.02% for ALZN’s stock, with a -63.80% simple moving average for the past 200 days.
Analysts’ Opinion of ALZN
Many brokerage firms have already submitted their reports for ALZN stocks, with Ascendiant Capital Markets repeating the rating for ALZN by listing it as a “Buy.” The predicted price for ALZN in the upcoming period, according to Ascendiant Capital Markets is $8 based on the research report published on October 01, 2021 of the previous year 2021.
ALZN Trading at -32.54% from the 50-Day Moving Average
After a stumble in the market that brought ALZN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -96.41% of loss for the given period.
Volatility was left at 9.03%, however, over the last 30 days, the volatility rate increased by 13.15%, as shares sank -32.08% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -37.54% lower at present.
During the last 5 trading sessions, ALZN fell by -18.81%, which changed the moving average for the period of 200-days by -84.66% in comparison to the 20-day moving average, which settled at $0.6837. In addition, Alzamend Neuro Inc saw -53.45% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ALZN starting from Horne William B., who purchase 3,334 shares at the price of $0.99 back on Mar 26 ’25. After this action, Horne William B. now owns 30,000 shares of Alzamend Neuro Inc, valued at $3,285 using the latest closing price.
AULT MILTON C III, the Director of Alzamend Neuro Inc, purchase 2,905 shares at $1.02 during a trade that took place back on Mar 21 ’25, which means that AULT MILTON C III is holding 85,273 shares at $2,969 based on the most recent closing price.
Stock Fundamentals for ALZN
Current profitability levels for the company are sitting at:
- -55.29 for the present operating margin
- 0.67 for the gross margin
The net margin for Alzamend Neuro Inc stands at -55.54. The total capital return value is set at -1.22. Equity return is now at value -1092.96, with -168.13 for asset returns.
Currently, EBITDA for the company is -9.89 million with net debt to EBITDA at 0.81. When we switch over and look at the enterprise to sales, we see a ratio of 2.77. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.44.
Conclusion
To wrap up, the performance of Alzamend Neuro Inc (ALZN) has been bad in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
